The state of Idaho currently has 15 active clinical trials seeking participants for Diabetes research studies. These trials are conducted in various cities, including Boise, Meridian, Idaho Falls and Nampa.
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
NCT06897475
Recruiting
The purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of semaglutide or tirzepatide. Participation in the study will last about 9 months.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/01/2025
Locations: Elite Clinical Trials, Rexburg, Idaho
Conditions: Type 2 Diabetes
Register for Updates
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
NCT06993792
Recruiting
The purpose of this Master Protocol is to support two studies to see how well and how safely orforglipron works compared to placebo in participants who have obesity or overweight with or without type 2 diabetes. Participants will be screened for about 4 weeks, after which they will enroll into either J2A-MC-GZP1, NCT06972459 (do not have type 2 diabetes) or J2A-MC-GZP2, NCT06972472 (have type 2 diabetes).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Solaris Clinical Research, Meridian, Idaho
Conditions: Obesity, Overweight, Type 2 Diabetes
Register for Updates
Enhance Study: Evaluation of Accuracy and Safety of the Eversense CGM System With Enhanced Features
NCT05131139
Recruiting
A Prospective, Multicenter Evaluation of Accuracy and Safety of the Eversense CGM System with Enhanced Features. The purpose of this clinical investigation is to evaluate the accuracy of the Eversense 524 Continuous Glucose Monitoring System (Eversense 524 CGM System) and ROME CGM System with next generation feature enhancements compared to reference glucose measurements in adults 18 years of age and older with diabetes. The investigation will also evaluate safety of the Eversense 524 CGM System... Read More
Gender:
ALL
Ages:
14 years and above
Trial Updated:
04/24/2023
Locations: Rocky Mountain Diabetes Center, LLC. (RMDC), Idaho Falls, Idaho
Conditions: Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Register for Updates